Sayre Therapeutics

At Sayre Therapeutics, we focus on bringing hitherto unavailable novel medicines, drug-delivery devices, companion diagnostics and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists and rheumatologists.These include, but are not limited to, small molecules, recombinant proteins,monoclonal antibodies (mAbs),drug-delivery devices and diagnostics in Oncology and Immunology.Our business model encompasses Global access / early access programs, Named Patient programs and securing product registrations for exclusive commercial distribution in South Asia

@sayretx (on twitter),@sayretx (on twitter),@sayretx (on twitter),@sayretx (on twitter),oncology,immunology,novel drugs,novel drug delivery systems,novel drug delivery devices,interventional oncology,neuro-oncology,branded generics,niche generics,molecular diagnostics,cdx,@sayretx (on twitter),@sayretx (on twitter),and @sayretx (on twitter)

Sayre therapeutics operates in the Biotechnology research industry.

Sayre therapeutics's revenue is 11m - 100m

Sayre therapeutics has 11 - 50 employees.